ZyVersa Therapeutics, Inc.
0.1400-0.01 (-4.11%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · ZVSA · USD
Key Stats
Market Cap
1.13MP/E (TTM)
-Basic EPS (TTM)
-1.94Dividend Yield
0%Recent Filings
8-K
CMO Guzman resigns abruptly
ZyVersa Therapeutics' Chief Medical Officer and Senior Vice President of Medical Affairs, Pablo Guzman, M.D., resigned on October 10, 2025, after joining in January 2015 with over 35 years in interventional cardiology. He steps down to focus on family and travel. No successor named yet. This leadership shift could disrupt clinical pipeline momentum.
8-K
Nasdaq delisting for ZyVersa
ZyVersa Therapeutics' common stock faces formal delisting from Nasdaq, with the exchange set to file Form 25 on September 18, 2025, effective ten days later, following suspension on July 17 for failing minimum bid price rules. Trading continues uninterrupted on the OTCQB under ZVSA. This shift reduces visibility and liquidity for investors. Delisting risks materializing as disclosed.
10-Q
Q2 FY2025 results
ZyVersa Therapeutics narrowed its Q2 operating loss to $2.0 million, down 26% year-over-year from $2.8 million, while research and development expenses dropped 42% to $0.4 million amid lower CRO fees and consultant costs for VAR 200 and IC 100 programs. The six-month net loss improved 20% to $4.5 million versus $5.6 million last year, with diluted EPS at $(1.13) on 3.97 million weighted shares—anti-dilution from 701,000 outstanding warrants and options excluded. Cash burn eased to $3.3 million used in operations for the half, funded by $2.0 million from a warrant private placement, leaving $72 thousand at quarter-end June 30, 2025, alongside a $12.1 million working capital deficit. No debt disclosed; a June 2025 equity line offers up to $10 million potential access. Post-quarter, Nasdaq delisted the stock to OTCQB on July 17, 2025, for bid price noncompliance. Penny stock rules now curb trading liquidity.
8-K
Stock approved for OTCQB trading
8-K
Nasdaq delisting hits ZyVersa
ZyVersa Therapeutics faces Nasdaq delisting after the Panel denied its appeal on July 15, 2025, for failing minimum bid price rules. Trading suspends July 17, shifting to the Pink Limited Market under ZVSA, potentially limiting liquidity and depressing share value. Yet the company eyes Council review within 15 days. Investors now navigate thinner markets.
ATOS
Atossa Therapeutics, Inc.
0.88-0.06
BIVI
BioVie Inc.
1.80-0.06
CALC
CalciMedica, Inc.
2.97-0.10
EDSA
Edesa Biotech, Inc.
2.07-0.09
KYMR
Kymera Therapeutics, Inc.
60.03-1.92
KZR
Kezar Life Sciences, Inc.
6.15-0.10
VERA
Vera Therapeutics, Inc.
29.36-0.60
XRTX
XORTX Therapeutics Inc.
0.65+0.02
ZURA
Zura Bio Limited
3.78+0.01
ZVRA
Zevra Therapeutics, Inc.
10.12-0.96